Axonics® Receives IDE Clearance from U.S. FDA to Conduct a Pivotal Study with its Sacral Neuromodulation System for the Treatment of Urinary Dysfunction
Axonics Modulation Technologies, Inc., developer of the first rechargeable sacral neuromodulation (r-SNM™) system for the treatment of overactive bladder (OAB) and bowel dysfunction, today announced the U.S. Food & Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) in accordance with 21 CFR 812 regulations allowing Axonics to conduct a pivotal study designed to gain FDA approval in the United States.
“During 2017, as part of the IDE process, the FDA conducted a significant review of our product. A major focus of the technical review was the long-term safety of our implant. The fact that we were able to support our anticipated 15-year full system life-in-the-body claim based on our robust design and development processes, risk analysis and extensive validation testing is testament to the high-quality work of our team,” said Raymond W. Cohen, Chief Executive Officer of Axonics. “Given the demand in the U.S. market for SNM therapy, gaining FDA approval is our main focus. To that end, we fully intend to execute this well-designed pivotal study with velocity and in the best interests of patients.”
Axonics expects to begin enrolling patients in the clinical study (ARTISAN-SNM) in November 2017, with a target of approximately 120 patients to be implanted at 15 centers of excellence located in the U.S. and Western Europe.
The ARTISAN-SNM study is a single-arm, prospective pivotal study designed to demonstrate the safety and effectiveness of the Axonics r-SNM system as an aid in the treatment of urinary urgency incontinence in patients who have failed or could not tolerate more conservative treatments.
Karen L. Noblett, M.D., Axonics Chief Medical Officer, stated, “The endpoints of the ARTISAN-SNM pivotal study are comparable to published clinical literature for urinary dysfunction. We will be analyzing, among other things, the proportion of responders to SNM therapy at six months post-implant based on reduction in urinary urgency incontinence episodes from the patient’s baseline diary. There has been an overwhelming response from the Urology and Urogynecology community to be part of this pivotal study and, as a result, we have some of the most experienced and prolific implanters as study investigators.”
During 2016, the Axonics r-SNM system gained regulatory approval in Europe and Canada for the treatment of overactive bladder, urinary urgency incontinence, urinary retention and fecal incontinence.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction. The Axonics r-SNM system includes a miniaturized rechargeable implantable neurostimulator qualified to function at least 15 years in the body, a charging system optimized for reduced charge time with no heating, a patient-friendly remote control and an intuitive clinician programmer that facilitates the lead placement procedure and programming. For more information, visit the Company’s website at www.axonicsmodulation.com .
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6322
Chief Operating & Financial Officer
Pure Communications, Inc.
Matt Clawson, +1-949-370-8500
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NY-21ST-CENTURY-FOX23.1.2018 08:31 | pressemeddelelse
21st Century Fox Welcomes the CMA’s Provisional Finding on Company’s Genuine Commitment to Broadcasting Standards
IDEMIA/OTONO-NETWORKS23.1.2018 07:32 | pressemeddelelse
IDEMIA Announces Acquisition of Otono Networks and Its eSIM Orchestration Solution
TAKEDA-PHARMACEUTICAL23.1.2018 07:32 | pressemeddelelse
Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year
CA-AECOM23.1.2018 06:02 | pressemeddelelse
AECOM defines infrastructure’s next chapter with launch of its inaugural global report: The Future of Infrastructure
CA-NEIL-DIAMOND23.1.2018 04:20 | pressemeddelelse
Neil Diamond Announces Retirement from Concert Touring; Australian and New Zealand Tour Dates Cancelled
CA-LOGITECH-INTL23.1.2018 03:02 | pressemeddelelse
Logitech Delivers Record Sales, Up 22%
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum